So should Y-mAbs Therapeutics (NASDAQ:YMAB) shareholders be worried about its cash burn? For the purposes of this article, cash burn is the annual rate at which an unprofitable co ...

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has presented the early-stage clinical data from its GD2-SADA PRIT trial at the Advances in Neuroblastoma Research (ANR) Meeting in Washington, D.C.The ...

Y-mAbs Therapeutics, Inc. (YMAB) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings. Skip to content Home ...